First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Slide 10 First phase 3a trial with oral semaglutide, PIONEER 1, in adults with type 2 diabetes completed Reduction in HbA1c with oral semaglutide, administered once daily as a tablet vs placebo HbA1c reduction (%)¹ Reduction in body weight with oral semaglutide, administered once daily as a tablet vs placebo Weight loss (kg)¹ Oral sema Oral sema Oral sema Placebo 3 mg 7 mg 14 mg 3 mg Oral sema Oral sema Oral sema 7 mg 14 mg Placebo 0.0 0.0 -0.1% -1.0 -0.4 -1.5 kg -2.0 -0.8 -1.7 kg -0.8 % -3.0 -2.5 kg -1.2 -1.3% -4.0 -1.6 -2.0 -1.5% -4.1 kg -5.0 1 Results illustrated by using the secondary statistical method called hypothetical estimand: Treatment effect, if all participants followed the treatment without rescue medication (analysed by using Mixed Models for Repeated Measurements (MMRM)). The statistical method is consistent with e.g. the statistical method used for the SUSTAIN programme for subcutaneous semaglutide. Sema: Semaglutide novo nordisk

View entire presentation